Eyenovia, Inc.

( )
EYEN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -5.12%51.490.9%$2175.18m
JNJJohnson & Johnson 2.22%162.920.7%$1364.82m
MRKMerck & Co., Inc. 0.12%73.430.7%$1062.62m
BMYBristol-Myers Squibb Co. 0.92%56.841.0%$817.37m
LLYEli Lilly & Co. 0.30%246.311.1%$708.15m
ABBVAbbVie, Inc. 2.10%121.341.9%$636.90m
AZNAstraZeneca Plc 2.18%55.411.0%$312.60m
NVSNovartis AG 0.66%80.530.2%$173.30m
GSKGlaxoSmithKline Plc 1.21%41.750.2%$159.14m
DRNADicerna Pharmaceuticals, Inc. -0.18%38.180.3%$155.33m
VTRSViatris, Inc. 1.97%12.440.0%$148.48m
RPRXRoyalty Pharma Plc 0.64%37.890.1%$117.35m
BFRIBiofrontera, Inc. -0.47%4.250.0%$113.12m
RGENRepligen Corp. -5.82%247.596.7%$93.01m
NVONovo Nordisk A/S 0.63%107.750.1%$82.81m

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.